文献速递认知障碍与痴呆脑血管病

血压、降压药使用与晚年阿尔茨海默病及非阿尔茨海默病痴呆风险:个体参与者数据荟萃分析

Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.
PubMed 文献 · Neurology · 2024-08-14

该个体参与者数据荟萃分析纳入14个国家31,250名社区老年人,评估高血压病史、降压药使用及基线血压与晚年阿尔茨海默病(AD)和非AD痴呆风险的关系。结果显示未治疗高血压与AD风险升高相关,降压药使用与AD风险降低相关,但基线单次血压测量与AD风险无关。

要点

  • 未治疗高血压者较健康对照AD风险升高(HR 1.36,95%CI 1.01-1.83)。
  • 未治疗高血压者较治疗高血压者AD风险升高(HR 1.42,95%CI 1.08-1.87)。
  • 治疗和未治疗高血压者非AD风险均高于健康对照,但治疗与未治疗组间无差异。

核心结论

  • 晚年使用降压药与AD风险降低相关,但与non-AD风险降低无关。
  • 晚年持续治疗高血压对降低AD风险仍然至关重要。
  • 单次血压测量与AD风险无关,但舒张压可能在较长晚年期间与non-AD风险呈U形关系。

研究设计与样本

  • 个体参与者数据荟萃分析,纳入既有联盟的社区纵向老龄化研究。
  • 共纳入来自14个国家的31,250名参与者,男性占41%,基线平均年龄72岁(SD 7.5,范围60-110岁)。
  • 主要结局为AD和非AD痴呆风险,主要暴露为高血压病史/降压药使用及基线收缩压/舒张压。
  • 采用混合效应Cox比例风险模型评估风险,并用自然样条模拟血压与痴呆结局的关系。
  • 主要模型控制年龄、年龄平方、性别、教育、种族群体和研究队列。

主要发现

  • 未治疗高血压者较健康对照AD风险升高(HR 1.36,95%CI 1.01-1.83,p=0.0406)。
  • 未治疗高血压者较治疗高血压者AD风险升高(HR 1.42,95%CI 1.08-1.87,p=0.0135)。
  • 治疗高血压者较健康对照non-AD风险升高(HR 1.29,95%CI 1.03-1.60,p=0.0267)。
  • 未治疗高血压者较健康对照non-AD风险升高(HR 1.69,95%CI 1.19-2.40,p=0.0032),但治疗与未治疗组间无差异。
  • 在随访5年以上的分析中,基线舒张压与non-AD风险呈显著U形关系(p=0.0227),其余分析中基线血压与AD或non-AD风险无显著关系。

临床怎么用

  • 作者认为,晚年持续治疗高血压对降低AD风险仍然至关重要。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Previous randomized controlled trials and longitudinal studies have indicated that ongoing antihypertensive use in late life reduces all-cause dementia risk, but the specific impact on Alzheimer dementia (AD) and non-AD risk remains unclear. This study investigates whether previous hypertension or antihypertensive use modifies AD or non-AD risk in late life and the ideal blood pressure (BP) for risk reduction in a diverse consortium of cohort studies. METHODS: This individual participant data meta-analysis included community-based longitudinal studies of aging from a preexisting consortium. The main outcomes were risk of developing AD and non-AD. The main exposures were hypertension history/antihypertensive use and baseline systolic BP/diastolic BP. Mixed-effects Cox proportional hazards models were used to assess risk and natural splines were applied to model the relationship between BP and the dementia outcomes. The main model controlled for age, age2, sex, education, ethnoracial group, and study cohort. Supplementary analyses included a fully adjusted model, an analysis restricting to those with >5 years of follow-up and models that examined the moderating effect of age, sex, and ethnoracial group. RESULTS: There were 31,250 participants from 14 nations in the analysis (41% male) with a mean baseline age of 72 (SD 7.5, range 60-110) years. Participants with untreated hypertension had a 36% (hazard ratio [HR] 1.36, 95% CI 1.01-1.83, p = 0.0406) and 42% (HR 1.42, 95% CI 1.08-1.87, p = 0.0135) increased risk of AD compared with "healthy controls" and those with treated hypertension, respectively. Compared with "healthy controls" both those with treated (HR 1.29, 95% CI 1.03-1.60, p = 0.0267) and untreated hypertension (HR 1.69, 95% CI 1.19-2.40, p = 0.0032) had greater non-AD risk, but there was no difference between the treated and untreated groups. Baseline diastolic BP had a significant U-shaped relationship (p = 0.0227) with non-AD risk in an analysis restricted to those with 5-year follow-up, but otherwise there was no significant relationship between baseline BP and either AD or non-AD risk. DISCUSSION: Antihypertensive use was associated with decreased AD but not non-AD risk throughout late life. This suggests that treating hypertension throughout late life continues to be crucial in AD risk mitigation. A single measure of BP was not associated with AD risk, but DBP may have a U-shaped relationship with non-AD risk over longer periods in late life.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lennon MJ, Lipnicki DM, Lam BCP, et al. Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis. Neurology. 2024. PMID: 39141884. doi:10.1212/WNL.0000000000209715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。